Reach Us +1-504-608-2390
Small Molecule Inhibitors Targeting The Th17 Cell Transcription Factor RORγt For The Treatment Of Autoimmune Diseases | 11137
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

7th International Congress on Infectious Diseases

Berlin, Germany

4th International Conference on Mass Spectrometry

Milan, Italy
Share This Page

Small molecule inhibitors targeting the Th17 cell transcription factor RORγt for the treatment of autoimmune diseases

2nd International Conference on Clinical & Cellular Immunology

Jianfei Yang

Keynote: J Clin Cell Immunol

DOI: 10.4172/2155-9899.S1.012

CD4 + Th17 cells, which are characterized by the expression of IL-17A, IL-17F, IL-22, IL-23R and CCR6, have been shown to play a critical role in a variety of autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, and asthma. IL-23 is critical for the differentiation of Th17 cells in vivo . Genome-wide association studies have demonstrated that Il23r polymorphisms are associated with several autoimmune diseases. Further, monoclonal antibodies against IL-12/IL-23p40 or IL-23p19 have shown spectacular efficacy in psoriasis patients. However, these antibodies target only a single cytokine and have limited efficacy in other autoimmune diseases.Thus, targeting Th17 lineage should result in better efficacy. The nuclear receptor ROR γ t has been shown to be the master transcription factor for the differentiation of Th17 cells as well as the expression of Th17 signature genes. We and several academic labs have discovered small molecule inhibitors of ROR γ t for the treatment of various diseases. The biology of ROR γ t has been extensively studied using ROR γ t small molecule inhibitors as tool compounds. The very recently advance of ROR γ t biology and its clinical application will be discussed.
Jianfei Yang is a Principal Scientist and a Project Leader of a Th17 cell-related project at Tempero Pharmaceuticals, a GSK company, in Cambridge, MA, USA. He received a Ph.D. in Pathology from Niigata University in Japan in 1997. He then obtained postdoctoral training in Dr. Ken Murphy?s lab at HHMI and Washington University. In the past 16 year, he has been studying the role of CD4 + T helper cells in immunity and diseases. He has more than 10 years of experience in autoimmune disease research and pharmaceutical drug development. He has published numerous papers and patents.